Hal Bar­ron’s GSK team con­tin­ues to cull res­pi­ra­to­ry drugs in big shift to on­col­o­gy R&D

The new R&D team un­der Hal Bar­ron is con­tin­u­ing to hack away at its res­pi­ra­to­ry pipeline.

The phar­ma gi­ant to­day sound­ed taps for six of its ex­per­i­men­tal drug pro­grams, leav­ing lit­tle doubt how its re­search pri­or­i­ties have shift­ed since Bar­ron was named R&D chief at the drug gi­ant.

In a foot­note to to­day’s quar­ter­ly up­date, which fo­cused con­sid­er­able at­ten­tion on on­col­o­gy af­ter the Tesaro buy­out and yes­ter­day’s bis­pe­cif­ic al­liance with Mer­ck­KGaA, GSK bid a fi­nal adieu to:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER